Results 11 to 20 of about 24,682,597 (289)
Cancer Management and Research, 2018 Bibi Kulsoom,1 Tahir Sultan Shamsi,1 Nasir Ali Afsar,2,3 Zahida Memon,4 Nikhat Ahmed,4 Syed Nazrul Hasnain5 1National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, Pakistan; 2Jinnah Medical and Dental College, Karachi, Pakistan ...
Kulsoom B +5 more
doaj +1 more source
Bcl-2 inhibitors: small molecules with a big impact on cancer therapy
, 2009 Despite tremendous advances over the last 15 years in understanding fundamental mechanisms of apoptosis, this has failed to translate into improved cancer therapy for patients. However, there may now be light at the end of this long tunnel. Antiapoptotic
M Vogler +7 more
core +7 more sources
Cancer-Associated BCL-2 Mutants Reveal Mechanisms Towards Venetoclax Resistance. [PDF]
Adv Sci (Weinh)Venetoclax (VEN) resistance in chronic lymphocytic leukemia arises from diverse BCL2 mutations. We map mechanisms contributing to VEN resistance across common BCL‐2 variants. G101V and D103Y reduce drug binding and increase sequestration of pro‐apoptotic proteins. V156D blocks VEN allosterically.
Aufdermauer J +9 more
europepmc +2 more sources
, 2023 (A) The BCL-2-regulated apoptotic pathway involves the following proteins pro-survival BCL-2 proteins, pro-apoptotic BH3-only proteins, and apoptosis effectors BAX/BAK proteins. Lines indicate interactions between molecules. (B) In healthy cells, the pro-
Nathaniel Chien (14636956) +6 more
core +1 more source
Molecular Interactions of Prodiginines with the BH3 Domain of Anti-Apoptotic Bcl-2 Family Members. [PDF]
, 2013 Prodigiosin and obatoclax, members of the prodiginines family, are small molecules with anti-cancer properties that are currently under preclinical and clinical trials. The molecular target(s) of these agents, however, is an open question.
Ali Hosseini (383134) +26 more
core +2 more sources
Potential mechanisms of resistance to venetoclax and strategies to circumvent it
BMC Cancer, 2017 Background Venetoclax (ABT-199), a first-in-class orally bioavailable BCL-2-selective inhibitor, was recently approved by the FDA for use in patients with 17p-deleted chronic lymphocytic leukemia who have received prior therapy.
Stephen K. Tahir +7 more
doaj +1 more source
Beyond cell death - antiapoptotic Bcl-2 proteins regulate migration and invasion of colorectal cancer cells in vitro. [PDF]
PLoS ONE, 2013 Migration and invasion of malignant cells are prerequisites for cancer progression and metastasis. The Bcl-2 family of proteins consists of about 25 members and has been extensively studied in the context of apoptosis.
Bruno Christian Koehler +9 more
doaj +1 more source
Cells, 2020 The dynamic interplay between pro-death and pro-survival Bcl-2 family proteins is responsible for a cell’s fate. Due to the recognized relevance of this family in cancer progression and response to therapy, different efforts have made in recent years in ...
Simona D’Aguanno, Donatella Del Bufalo
doaj +1 more source
Suppression of signal transducer and activator of transcription 3-dependent B lymphocyte terminal differentiation by BCL-6 [PDF]
, 2000 Lymphocytes usually differentiate into effector cells within days after antigen exposure, except in germinal centers where terminal differentiation is delayed while somatic hypermutation creates high-affinity antibody mutants. Here we investigate whether
Peakman, LJ +14 more
core +1 more source
Pramanicin analog induces apoptosis in human colon cancer cells: critical roles for Bcl-2, Bim, and p38 MAPK signaling [PDF]
, 2013 Pramanicin (PMC) is an antifungal agent that was previously demonstrated to exhibit antiangiogenic and anticancer properties in a few in vitro studies. We initially screened a number of PMC analogs for their cytotoxic effects on HCT116 human colon cancer
Karslı, Gizem +23 more
core +2 more sources